Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Portland, Oregon

CNS medication trials in Portland, OR

26 CNS medication studies are recruiting participants at sites in Portland as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Portland at a glance

  • 26 studies are recruiting at a site in Portland.
  • By phase: Phase 1/2 (1), Phase 2 (4), Phase 2/3 (1), Phase 3 (15), Phase 4 (5).
  • By sponsor: industry (20), government (4), university, hospital or other (2).
  • By research area: Migraine (7), Parkinson's Disease (7), Depression (5), ADHD (3), Epilepsy (3), Multiple Sclerosis (1).
  • Most recent update to one of these records: November 16, 2026.

Depression studies recruiting in Portland

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study site
    Summit Headlands (Headlands Research)
    Registry record
    NCT07226661 · updated
  2. A Study of Brenipatide in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Summit Headlands
    Registry record
    NCT07412756 · updated
  3. Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    VA Office of Research and Development
    Study site
    VA Portland Health Care System, Portland, OR
    Registry record
    NCT07226232 · updated
  4. Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07484217 · updated
  5. A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

    • Phase 4
    • Ages 18 to 65
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT06223880 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Portland, OR on ClinicalTrials.gov.

ADHD studies recruiting in Portland

  1. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

    • Phase 3
    • Ages 6 to 11
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717879 · updated
  2. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717892 · updated
  3. A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Otsuka Pharmaceutical Development & Commercialization, Inc.
    Study site
    Summit Research Network
    Registry record
    NCT07759154 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Portland, OR on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Portland

  1. An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

    • Phase 2
    • Ages 50 to 80
    • All sexes
    Sponsor
    Yale University
    Study site
    Oregon Health & Science University
    Registry record
    NCT06996652 · updated
  2. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Oregon Health and Science University
    Registry record
    NCT07174310 · updated
  3. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    • Phase 2
    • Ages 40 to 80
    • All sexes
    Sponsor
    Neuron23 Inc.
    Study site
    Oregon Health & Science University (OHSU)
    Registry record
    NCT06680830 · updated
  4. A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

    • Phase 2/3
    • Ages 40 to 80
    • All sexes
    Sponsor
    Biohaven Therapeutics Ltd.
    Registry record
    NCT06976268 · updated
  5. A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Providence Portland Medical Center ( Site 0044) · Providence St. Vincent Medical Center ( Site 0081)
    Registry record
    NCT06312176 · updated
  6. Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

    • Phase 4
    • Ages 40 and older
    • All sexes
    Sponsor
    VA Office of Research and Development
    Study site
    VA Portland Health Care System, Portland, OR
    Registry record
    NCT04373317 · updated
  7. Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

    • Phase 2
    • Ages 18 and older
    • Male participants
    Sponsor
    Mark Garzotto, MD
    Study site
    VA Portland Healthcare System
    Registry record
    NCT03753243 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Portland, OR on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Portland

  1. Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

    • Phase 3
    • Ages 40 to 70
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Providence Neurological Services West
    Registry record
    NCT06846281 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Portland, OR on ClinicalTrials.gov.

Epilepsy studies recruiting in Portland

  1. Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits

    • Phase 4
    • Ages 18 and older
    • All sexes
    Sponsor
    VA Office of Research and Development
    Study site
    VA Portland Health Care System, Portland, OR
    Registry record
    NCT04419272 · updated
  2. A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    Providence Neurological Specialities
    Registry record
    NCT05716100 · updated
  3. A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

    • Phase 1/2
    • From 6 months, up to 17 years
    • All sexes
    Sponsor
    Encoded Therapeutics
    Study site
    Oregon Health and Science University (OHSU)
    Registry record
    NCT05419492 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Portland, OR on ClinicalTrials.gov.

Migraine studies recruiting in Portland

  1. Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

    • Phase 4
    • Ages 18 to 70
    • All sexes
    Sponsor
    Mayo Clinic
    Study site
    Advanced Research Institute
    Registry record
    NCT06972056 · updated
  2. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study sites
    Advanced Research Institute - Portland · Summit Research Network
    Registry record
    NCT07645924 · updated
  3. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study sites
    Advanced Research Institute-Portland · Summit Research Network
    Registry record
    NCT07674654 · updated
  4. Randomized Study in Children and Adolescents With Migraine: Acute Treatment

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study sites
    Providence Neuroscience Institute - Research Coordinator's Office · Providence St. Vincent Medical Center
    Registry record
    NCT04649242 · updated
  5. Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study sites
    Providence Neuroscience Institute: Research Coordinators' Office · Providence Pediatric Specialty Clinic
    Registry record
    NCT04743141 · updated
  6. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Providence Brain and Spine Institute /ID# 231607
    Registry record
    NCT05125302 · updated
  7. Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old

    • Phase 4
    • Ages 6 to 11
    • All sexes
    Sponsor
    Upsher-Smith Laboratories
    Study site
    Upsher-Smith Clinical Trial Site #6
    Registry record
    NCT04748601 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Portland, OR on ClinicalTrials.gov.

Ask about studies near Portland

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call